Actively Recruiting
Anticoagulation-free VV ECMO for Acute Respiratory Failure
Led by Damian Ratano · Updated on 2026-01-16
40
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
Sponsors
D
Damian Ratano
Lead Sponsor
T
The Physicians' Services Incorporated Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an "anticoagulation-free strategy" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).
CONDITIONS
Official Title
Anticoagulation-free VV ECMO for Acute Respiratory Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient with ARDS on VV-ECMO
You will not qualify if you...
- Contraindication to anticoagulation with UFH such as known heparin-induced thrombocytopenia, active hemorrhage, or recent surgery preventing anticoagulation
- Indication for therapeutic anticoagulation including pulmonary embolism, deep vein thrombosis, or chronic anticoagulation therapy before ECMO
- Low-flow VV-ECMO less than 2 liters per minute (ECCO2R)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2N2
Actively Recruiting
Research Team
D
Damian Ratano, MD
CONTACT
E
Eddy Fan, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here